Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00479388 |
This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.
Condition | Intervention | Phase |
---|---|---|
Primary Hypercholesterolemia Mixed Dyslipidemia |
Drug: Comparator: simvastatin Drug: niacin (+) laropiprant Drug: Comparator: atorvastatin calcium |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. |
Enrollment: | 1250 |
Study Start Date: | July 2007 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
|
Drug: niacin (+) laropiprant
One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
|
2: Active Comparator
Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
|
Drug: Comparator: simvastatin
simvastatin (20mg to 40mg) for 12 weeks.
Drug: Comparator: atorvastatin calcium
atorvastatin calcium (20mg to 40mg) for 12 weeks.
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2007_521, MK0524A-067 |
Study First Received: | May 24, 2007 |
Last Updated: | July 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00479388 History of Changes |
Health Authority: | Canada: Health Canada |
Antimetabolites Vasodilator Agents Vitamin B Complex Hyperlipidemias Metabolic Diseases Niacinamide Simvastatin Antilipemic Agents Trace Elements Anticholesteremic Agents Cardiovascular Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Nicotinic Acids Calcium, Dietary Vitamins Micronutrients Hypercholesterolemia Metabolic Disorder Niacin Dyslipidemias Atorvastatin Lipid Metabolism Disorders |
Antimetabolites Vasodilator Agents Vitamin B Complex Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Simvastatin Growth Substances Antilipemic Agents Physiological Effects of Drugs Enzyme Inhibitors Anticholesteremic Agents |
Cardiovascular Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Vitamins Therapeutic Uses Micronutrients Hypercholesterolemia Niacin Dyslipidemias Atorvastatin Lipid Metabolism Disorders |